A COMPARISON OF MARROW TRANSPLANTATION WITH CHEMOTHERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN 2ND OR SUBSEQUENT REMISSION
A COMPARISON OF MARROW TRANSPLANTATION WITH CHEMOTHERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN 2ND OR SUBSEQUENT REMISSION
复制标题
DOI：
10.1056/nejm198110083051502
复制
发表时间：
1981-01-01
影响因子：
158.5
通讯作者：
STORB, R
中科院分区：
文献类型：
--
作者：
JOHNSON, FL;THOMAS, ED;STORB, R
24例急性淋巴细胞白血病患儿在第二次或随后的缓解期接受环磷酰胺、全身照射和骨髓移植治疗，与21例进入第二次缓解期后接受常规化疗的患儿进行比较。移植组11例存活，其中9例持续完全缓解17-55个月，化疗组仅有2例存活，1例在20个月后完全缓解。复发是两组失败的主要原因。急性和慢性移植物vs。移植组的-宿主病和两组的白质脑病是发病率和死亡率的其他主要原因。显然，骨髓移植目前是急性淋巴细胞白血病患儿骨髓复发后长期缓解和潜在治愈的最佳机会。
The progress of 24 children with acute lymphoblastic leukemia treated with cyclophosphamide, total-body irradiation and marrow transplantation during a 2nd or subsequent remission was compared with that of 21 children treated with conventional chemotherapy after they had entered a 2nd remission. Eleven of the transplantation group are alive, including 9 in continuing complete remission for 17-55 mo., only 2 of the chemotherapy group are alive, 1 in complete remission after 20 mo. Relapse was the major cause of failure in both groups. Acute and chronic graft-vs.-host disease in the transplantation group and leukoencephalopathy in both groups were the other major causes of morbidity and mortality. Marrow transplantation evidently currently offers the best chance of long-term remission and potential cure after a child with acute lymphoblastic leukemia has had a relapse in the marrow.